Zobrazeno 1 - 2
of 2
pro vyhledávání: '"the PLATCOV Collaborative Group"'
Autor:
Viravarn Luvira, William H. K. Schilling, Podjanee Jittamala, James A. Watson, Simon Boyd, Tanaya Siripoon, Thundon Ngamprasertchai, Pedro J. Almeida, Maneerat Ekkapongpisit, Cintia Cruz, James J. Callery, Shivani Singh, Runch Tuntipaiboontana, Varaporn Kruabkontho, Thatsanun Ngernseng, Jaruwan Tubprasert, Mohammad Yazid Abdad, Srisuda Keayarsa, Wanassanan Madmanee, Renato S. Aguiar, Franciele M. Santos, Pongtorn Hanboonkunupakarn, Borimas Hanboonkunupakarn, Kittiyod Poovorawan, Mallika Imwong, Walter R. J. Taylor, Vasin Chotivanich, Kesinee Chotivanich, Sasithon Pukrittayakamee, Arjen M. Dondorp, Nicholas P. J. Day, Mauro M. Teixeira, Watcharapong Piyaphanee, Weerapong Phumratanaprapin, Nicholas J. White, the PLATCOV Collaborative Group
Publikováno v:
BMC Infectious Diseases, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Brief summary In early symptomatic COVID-19 treatment, high dose oral favipiravir did not accelerate viral clearance. Background Favipiravir, an anti-influenza drug, has in vitro antiviral activity against SARS-CoV-2. Clinical trial evidence
Externí odkaz:
https://doaj.org/article/38be8586c0b14f9a9e31989e8009d6df
Autor:
William HK Schilling, Podjanee Jittamala, James A Watson, Maneerat Ekkapongpisit, Tanaya Siripoon, Thundon Ngamprasertchai, Viravarn Luvira, Sasithorn Pongwilai, Cintia Cruz, James J Callery, Simon Boyd, Varaporn Kruabkontho, Thatsanun Ngernseng, Jaruwan Tubprasert, Mohammad Yazid Abdad, Nattaporn Piaraksa, Kanokon Suwannasin, Pongtorn Hanboonkunupakarn, Borimas Hanboonkunupakarn, Sakol Sookprome, Kittiyod Poovorawan, Janjira Thaipadungpanit, Stuart Blacksell, Mallika Imwong, Joel Tarning, Walter RJ Taylor, Vasin Chotivanich, Chunlanee Sangketchon, Wiroj Ruksakul, Kesinee Chotivanich, Mauro Martins Teixeira, Sasithon Pukrittayakamee, Arjen M Dondorp, Nicholas PJ Day, Watcharapong Piyaphanee, Weerapong Phumratanaprapin, Nicholas J White, on behalf of the PLATCOV Collaborative Group
Publikováno v:
eLife, Vol 12 (2023)
Background: There is no generally accepted methodology for in vivo assessment of antiviral activity in SARS-CoV-2 infections. Ivermectin has been recommended widely as a treatment of COVID-19, but whether it has clinically significant antiviral activ
Externí odkaz:
https://doaj.org/article/e2c1da5e8a0a4bd4bce22cc5135ee7e1